EUCTR2008-000452-27-BE进行中（未招募）1 期
A Pharmacokinetic, Pharmacodynamic and Safety Study of Single and Multiple Doses of Rabeprazole in Pediatric Subjects with GERD 1 to 11 Months old, Inclusive
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 49
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must satisfy the following criteria to be enrolled in the study:
- •1.Boys or girls, ages 1 to 11 months (up to 11 months 29 days), inclusive, and a minimum weight of 5 kg (treatment Option 1) or 3 kg (treatment Option 2)with a diagnosis of GERD.
- •2.As approved by institutional specific guidelines, the subject’s parent (preferably both parents if available) must sign an informed consent form before the performance of any study procedures indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
- •3.Subjects who have been treated with, or are currently receiving a proton pump inhibitor (PPI), H2 blockers, or antacids are eligible (as long as they can go off antacids for 24 hours, and PPIs and H2 blockers for three days prior to dosing, except for cimetidine, which must be discontinued for at least seven days prior to dosing) and remain off these medications for the treatment period
- •4.The subject’s parent must be willing to adhere to prohibitions and restrictions outlined in the protocol
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects who meet any of the following criteria will be excluded from participating in the study:
- •1.History of or current clinically significant medical illness (excluding GERD) including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, infection, or any other illness that the investigator considers should exclude the subject or that could interfere with the interpretation of the study results
- •2.Primary pulmonary or ENT symptoms, eg, bronchospasm, aspiration pneumonia, chronic nasal blockage, cough, recurrent croup-like cough, stridor, hoarseness, laryngitis, recurrent bronchitis, laryngospasm, nocturnal asthma, bronchopulmonary dysplasia which are primary disease processes and not deemed to be secondary to GERD
- •3.Presence of warning signals”, eg, bilious vomiting, GI bleeding (hematemesis, hematochezia), forceful vomiting, fever, lethargy, hepatosplenomegaly, urinary tract infections, macro/microcephaly, seizures, genetic disorders (eg, trisomy 21), suggesting cause of vomiting/regurgitation other than GERD
- •6. history of peptic ulcers
- •12.Uncorrected electrolyte disorders (such as hypokalemia, hypocalcemia, hypomagnesemia with normal reference for age)
- •13.Known chromosome abnormality or congenital anomalies of the gastrointestinal tract, heart or liver; including, eg, obstruction, atresias (other than gastrointestinal tract immaturity)
- •14.Serum concentrations of hepatic transaminases >3-fold higher than the upper limit of normal for age and/or creatinine ³106 mmoles/L
- •15.Clinically relevant laboratory values outside the normal age appropriate range. If the results of the testing are not within the laboratory’s reference range for the subject’s age, the subject may be included only if the investigator decides the abnormal values are not clinically significant. Laboratory results taken from the subject’s history if performed within 48 hours prior to screening are allowed, in lieu of a laboratory draw
- •16.Participation in any investigational drug or medical device trial prior to selection within 30 days or within a period less than 10 times the drug’s half life, whichever is longer, before the first dose of the study drug is scheduled
- •17.Any condition which would make the patient, in the opinion of the Investigator or Sponsor, unsuitable for the study
- •18.Treatment with full therapeutic doses of H2-receptor antagonists or sucralfate within three days prior to dosing (or a shorter washout if agreed to by Investigator and Sponsor), except for cimetidine, which must be discontinued for at least seven days prior to dosing
- •19.Treatment with a proton pump inhibitor within three days prior to dosing (or a shorter washout if agreed to by Investigator and sponsor)
- •20.A history of allergy/sensitivity to proton pump inhibitors or to their inactive ingredients
- •22.Known allergy to heparin or history of heparin-induced thrombocytopenia
- •23.Donated blood or blood products or had substantial loss of blood (more than 7 mL/kg) within 3 months before the first administration of study drug
- •24.Preplanned surgery or procedures that would interfere with the conduct of the study
- •25.A subject’s parent or the legally acceptable representative is an employee of the investigator or study center, with direct involvement in the proposed study or
研究者
相似试验
进行中（未招募）
1 期
Study of Rabeprazole in Pediatric Subjects aged 1 to 11 months with acid reflux diseasePediatric subjects with GERDMedDRA version: 13.1 Level: LLT Classification code 10018203 Term: GERD System Organ Class: 10017947 - Gastrointestinal disordersEUCTR2008-000452-27-GBJanssen-Cilag International N.V.49
招募中
1 期
Safety, pharmacokinetics and pharmacodynamics study of Leucettinib-21 in healthy subjects, Down Syndrom and Alzheimer patientsA Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses and Food Effect of Leucettinib-21 in Healthy Male Subjects, followed by an open single dose of Leucettinib-21 in Down Syndrome individuals, and patients with Alzheimer’s diseaseCTIS2023-507075-22-00Eurofins Optimed120
已完成
1 期
Study to evaluate the effects of new drug of diabetes mellitus in healthy volunteers.CTRI/2016/01/006507Cadila Pharmaceuticals Ltd36
已完成
不适用
A Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Doses of LY3526318 in Healthy ParticipantsNL-OMON50998Eli Lilly16
进行中（未招募）
1 期
Safety, Tolerability and Pharmacokinetics of Tirzepatide in Pediatric Participants with Obesity.Weight managementMedDRA version: 20.0Level: HLTClassification code 10027428Term: Metabolic disorders NECSystem Organ Class: 100000004861EUCTR2024-000081-22-Outside-EU/EEAEli Lilly and Company